Altered monocyte activation markers in Tourette’s syndrome: a case–control study

Judith Matz†, Daniela L. Krause††*, Sandra Dehning1, Michael Riedel1,2, Rudolf Gruber3, Markus J. Schwarz1 and Norbert Müller1

Abstract

Background: Infections and immunological processes are likely to be involved in the pathogenesis of Tourette’s syndrome (TS). To determine possible common underlying immunological mechanisms, we focused on innate immunity and studied markers of inflammation, monocytes, and monocyte-derived cytokines.

Methods: In a cross-sectional study, we used current methods to determine the number of monocytes and levels of C-reactive protein (CRP) in 46 children, adolescents, and adult patients suffering from TS and in 43 healthy controls matched for age and sex. Tumor necrosis factor alpha (TNF-alpha), interleukin 6 (IL-6), soluble CD14 (sCD14), IL1-receptor antagonist (IL1-ra), and serum neopterin were detected by immunoassays.

Results: We found that CRP and neopterin levels and the number of monocytes were significantly higher in TS patients than in healthy controls. Serum concentrations of TNF-alpha, sIL1-ra, and sCD14 were significantly lower in TS patients. All measured values were within normal ranges and often close to detection limits.

Conclusions: The present results point to a monocyte dysregulation in TS. This possible dysbalance in innate immunity could predispose to infections or autoimmune reactions.

Background

Tourette’s syndrome (TS) is a neuropsychiatric disorder that is characterized by childhood onset of multiple motor tics and at least one vocal tic. The disease shows exacerbations and remissions over time. Obsessive-compulsive disorder (OCD), attention deficit hyperactivity disorder (ADHD), mood disorders, and behavioral problems are often associated with TS [1]. TS can lead to social impairment, psychological distress, and discrimination; extreme forms of this disorder include self-injurious motor tics and coprolalia. Epidemiological studies show that TS is relatively common, with an estimated overall worldwide prevalence of 1% [2] and an even higher prevalence among children. Boys are affected about 4 times more often than girls [3]. The results of different studies point to a multifactorial pathogenesis of TS, with an interaction of genetic, environmental, hormonal, and immunological factors [4]. The exact pathogenic mechanisms are still unclear, but a disturbed dopaminergic neurotransmission in the basal ganglia-striato-thalamo-cortical circuits seems to generate tic expression as a common endpoint. Genetics play also an important role in the disease etiology of TS. However, TS is likely to be genetically heterogeneous and until now no loci have been definitely confirmed. Twin studies support a significant role for non-genetic influences [5].

One important hypothesis is that infections could trigger the onset of TS or tic exacerbations. Signs of acute or chronic infections have been observed in TS patients [6]. As both acute infections with A beta-hemolytic streptococcus (GABHS) [7,8] and poststreptococcal inflammation [9] have been reported to be associated with TS, TS has been proposed to be one of the pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection (PANDAS) [10,11], similar to the pathophysiological model of Sydenham’s chorea. Moreover, increased streptococcal antibodies and signs of inflammation have been observed in adult TS patients [12,13]. Nevertheless, the topic of PANDAS is contentious, and it is not clear whether it is a distinct clinical entity [14]. Also, infections with Borellia burgdorferi [15], acute or chronic infections with Mycoplasma
pneumoniae [12,13], and viral infections [16] have been reported to trigger tic exacerbations. Recently, we could report significantly more positive IgG antibody titers against Chlamydia trachomatis in TS patients than in healthy controls and a trend to higher antibody titers of Toxoplasma gondii in TS patients [17]. Both pathogens can invade the brain parenchyma. The role of autoantibodies against neuronal structures in TS is still controversial, and the causality is not proven; however, autoantibodies against neuronal structures could be one possible pathophysiological model for a subgroup of TS patients.

Another important hypothesis is the existence of a common underlying altered immune status that results in an insufficient clearing of infectious agents and triggers the onset of TS or worsening of tics. The innate immune system in particular is important for the first immune response. For this reason, we investigated monocytes; the mainly monocyte-derived cytokines tumor necrosis factor alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-1 receptor-antagonist (IL1-ra); and monocyte-derived soluble CD14 (sCD14). Cells of the monocyte/macrophage lineage phagocytize foreign material, present antigens to T-cells and produce proinflammatory cytokines, such as TNF-alpha, IL-1, and IL-6. Peripheral cytokines are known to be able to cross the blood–brain barrier and influence neuronal brain functions, even in low concentrations [18].

To our knowledge, so far no studies have focused mainly on monocytes and monocyte-derived parameters in TS and only a few studies have investigated the role of cytokines in TS. Leckman et al. [19] reported increased serum levels of TNF-alpha and IL-12 in juvenile TS patients. This is an interesting finding, because in OCD decreased levels of TNF-alpha were described [20-22]. Since OCD and TS show a high rate of co-morbidity [23], it would be of interest to find a possible discriminative marker (e.g. cytokines that are decreased in OCD and increased in TS) for the two disorders. Gabbay et al. investigated juvenile TS patients and reported higher IL-12 plasma levels in TS/OCD patients than in controls and higher IL-2 in the subgroup of TS/OCD patients than in TS patients without OCD [24]. Bos-Veneman et al. [25] did not evaluate findings of an immune activation or differences between TS and controls, but did find that serum IL-2 concentrations were positively associated with tic severity ratings.

Soluble CD14 plays an important role in innate immunity. Monocytes carry the surface marker CD14, a membrane-bound or soluble glycoprotein that mediates the interaction of lipopolysaccaride (LPS; a component of the cell surface of gram-negative bacteria) and of lipoteichoic acid (LTA; a component of different gram-positive bacteria) with cells. Mycoplasma pneumoniae can also be recognized by LPS-binding protein [26]. Soluble CD14 additionally enhances the immune response to LPS in cell types that lack the CD14 receptor on their surface [26], i.e. sCD14 is a co-activator for many cell types in the cascade of immune activation in response to a monocytic signal [27,28]. Decreased sCD14 levels point to a decreased state of monocyte activation. It has been postulated that sCD14 is important for the development of the T cell subset balance [29]. Reduced sCD14 levels in breast milk have been reported to be associated with the occurrence of atrophy and eczema [30]. So far, sCD14 has not been investigated in TS patients. Recently, reduced natural regulatory T (Tregs) cells in children with TS or OCD or both were reported, indicating a predisposition for overriding autoimmune responses [31].

To detect a possible (chronic) inflammatory state in TS patients, we measured neopterin and C-reactive protein (CRP), the most common and sensitive markers for an inflammatory process.

The study focused on innate immunity, because disturbances in innate immunity could explain an increased susceptibility to infectious agents.

Methods

In a cross-sectional study performed at the Department of Psychiatry and Psychotherapy, Ludwig Maximilian University (LMU), Munich, Germany, we examined 46 TS patients and 43 age- and sex-matched healthy controls. All 46 TS patients fulfilled the DSM-IV-TR diagnostic criteria [32] for TS. Diagnoses were made by two independent experienced psychiatrists. Tic severity was quantified with the Tourette’s Syndrome Global Scale (TSGS) [33], and co-morbid OCD with the Maudsley Obsessive-Compulsive Inventory (MOCI) [34]. As a cut-off value for the group with OCD, study participants with a MOCI value of ≥12 were chosen (maximum value 30 points) [35]. The mean duration of TS was 21.1 years. The 43 healthy controls were recruited from the general population in Munich by advertisements. An experienced psychiatrist performed structured clinical interviews to exclude any psychiatric disorders. Exclusion criteria for patients and healthy controls were acute infections and immunological, neurological, or other medical disorders and were checked by assessing the medical history, clinical examination, and laboratory measurements (CRP, differential blood count, basic parameters of clinical chemistry). No treatment with corticosteroids or other immune-modulating agents was allowed. All study participants were Caucasians. Written informed consent was obtained from all study participants. If study participants were younger than 18 years, at least one parent had to give informed consent. The study was approved by the ethics committee of the LMU medical faculty.

A total of 18 ml blood was drawn from each participant: 3 ml EDTA blood was used for the differential blood count; 7.5 ml heparin blood, to determine CRP and basic...
clinical chemistry parameters (electrolytes, liver and kidney parameters, TSH); and 7.5 ml whole blood, to extract serum for later immunoassays. Within 30 minutes after vein puncture, 7.5 ml whole human blood was centrifuged at 3500 rpm at 4°C for 10 minutes and the extracted serum was aliquoted and stored at −80°C for later measurements. The differential blood count included a monocyte count and was performed on a hematology analyzer (Coulter STKS). CRP and basic clinical chemistry parameters were measured on an automated analyzer (ROCHE, Hitachi 912). To detect TNF-alpha and IL-6, we used the Bio-Plex cytokine assay and the cytokine reagent and diluent kit (Bio-Rad, Munich). The Bio-Plex system combines the principle of a sandwich immunoassay with Luminex fluorescent bead technology. The lower limits of detection were 0.2 pg/ml for TNF-alpha and 1.7 pg/ml for IL-6. sCD14 was detected in serum by using the Quantikine soluble CD14 Immunoassay (R&D Systems, Minneapolis), with a lower limit of detection of 0.25 ng/ml. Neopterin was measured with the neopterin solid phase enzyme-linked immunosorbent assay (IBL, Hamburg); the lower detection limit was 1.35 nmol/l. For IL1-ra, we used the Quantikine IL1-ra Immunoassay (R&D Systems, Minneapolis) with a lower limit of detection of 0.047 ng/ml. All assays were done according to the respective manufacturer’s instructions for use.

We used the SPSS 13.0.1. statistic program for statistical analysis. Data are given in means ± standard deviation (SD). Since some data did not pass the Kolmogorov-Smirnov test for normality, Mann–Whitney U tests were used to test differences between the patient and healthy control groups. P-values below alpha ≤ 0.05 were considered significant, and all tests were two-tailed. As the analyses were exploratory in nature and the monocyte-derived products seemed to be highly correlated, we did not correct for multiple tests. Results have to be interpreted accordingly. In addition, the results were analyzed by Kruskal-Wallis ANOVA and alpha-corrected post hoc Mann–Whitney U tests. Pearson’s correlation coefficients were calculated to test for possible correlations, and proportional data were analyzed by using Fisher’s exact test to test for homogeneity in the two groups.

Results
Study demographics
We found no significant differences between the two groups concerning age ($\chi^2_1 = 1.16, p = 0.60$) or gender ($\chi^2_1 = 0.83, p = 0.47$). Demographic data are summarized in Table 1.

The medical history and basic clinical chemistry parameters showed no signs of any serious diseases, including hypo- or hyperthyreosis or acute infections, in either TS patients or healthy controls.

Immune markers in Tourette’s syndrome
The mean number of monocytes/ml blood, CRP levels, and serum neopterin concentration were all significantly higher in TS patients than in healthy controls. However, these levels were within normal ranges in both groups. In contrast, the mean serum TNF-alpha concentration was significantly lower in TS patients than in healthy controls. IL-6 serum levels showed no differences between groups. Mean serum concentrations of sCD14 and mean IL1-ra concentrations were significantly lower in TS patients (see Table 2).

Subgroup analyses of TNF-alpha, IL1-ra, sCD14, and neopterin did not reveal any differences between non-medicated and medicated TS patients. Similarly, no differences were seen between TS patients with and those without co-morbid OCD. Interestingly, the subgroup analyses revealed stronger differences in the comparison between TS patients with co-morbid OCD and healthy controls. These findings are shown in Table 3.

Analyses of TNF-alpha, sCD14, IL1-ra, and neopterin for age subgroups are summarized in Table 4. Within the TS group, these parameters did not differ between children/adolescents and adults. Within the healthy control group, IL1-ra differed significantly between healthy children/adolescents and healthy adults; none of the other parameters differed between these two subgroups. Significant differences were found between healthy and TS children/adolescents for TNF-alpha, IL1-ra, and sCD14 and between healthy and TS adults for IL-1-ra, sCD14, and neopterin. Some of the subgroups were small, and the results have to be interpreted accordingly.

The neopterin concentration correlated significantly and positively with age in the patient group ($r = 0.355, p = 0.02$). None of the parameters correlated significantly with tic severity.

Discussion
There is growing evidence that immunological mechanisms contribute to the pathophysiology of TS, at least in a subgroup of TS patients. We hypothesized that TS has a common underlying immune mechanism that possibly causes a disturbed clearing of infectious agents. As innate immunity plays an important role in the first-line immune response, in our study we focused on monocytes/macrophages and associated parameters.

Our results are in line with previous findings: Leckman et al. [19] reported signs of an increased activation of the cellular type-1 immune response in TS. At baseline, the authors found higher concentrations in TS patients than in controls of both the T cell (type 1) cytokine IL-12 and monocyte-derived TNF-alpha; the latter finding was in contrast to our findings. Even higher concentrations of these parameters were found in patients in a state of symptom exacerbation. Interestingly, these observations...
were more frequent in non-PANDAS than in PANDAS patients. Leckman et al. found no differences in the levels of other cytokines such as IL-1, IL-4, IL-6, IL-10, and IFN-γ [19]. In our sample, TNF-alpha serum levels were lower in TS patients than in healthy controls. Besides methodological differences, several factors could explain the differences between our findings. For example, our sample had a higher number of unmedicated patients. Our medicated patients received mainly dopamine antagonists, whereas patients in the study by Leckman et al. received mainly alpha-agonists. Certain antipsychotics are known to increase TNF-alpha levels [36], so our sample may have actually had even lower TNF-alpha levels if they had been in an unmedicated state. Although our sample size was limited, and the subgroups were particularly small, we did not find a significant influence of medication on any parameters, including TNF-alpha. Another contributing factor could be age [37] and disease stage. In our sample one limitation was the age range of study participants. This is why subanalyses were performed: healthy children/adolescents showed the highest serum TNF-alpha levels, followed by healthy adults, TS children/adolescents, and TS adults. When the subgroup of TS children/adolescents and TS adults were compared with the respective healthy control age groups, differences were seen between both age groups in almost all parameters. Given the high comorbidity of OCD and TS [23], our results in regard to TNF-alpha levels are in accordance with reports of decreased TNF-alpha levels in OCD [20-22]. In our sample, the subgroup analysis of patients with and those without co-morbid ODC symptoms revealed no significant difference in the levels of any of the determined parameters, including TNF-alpha. This result indicates that in our sample the occurrence of co-morbid OCD seems to have no relevant influence on TNF-alpha levels. The same is true for other parameters, although the small size of the samples limits the interpretation of the findings. However, the trend of stronger effects in the comparison of healthy controls with TS patients with co-morbid ODC is noteworthy and in parallel with the findings of Gabbay et al. concerning IL-12 [24]. It has to be mentioned that in our study the subgroups of TS patients and TS patients with OCD could eventually suffer from a co-morbid ADHD. The structured clinical interviews did not show hints for ADHD in all study participants, however, in order to exclude ADHD entirely, a specific ADHD rating scale should be applied in future studies. Another limitation of this study is that the used rating scales (MOCI and TSGS) are reliable, but are less frequently used then for example the Yale-Brown Obsessive-Compulsive Scale and do not represent the ‘gold standard’.

Table 1 Demographic features and clinical characteristics of TS patients and healthy controls

| Variable                        | Group          | Mean ± SD (range) | n   | TS patients          | n   | Healthy controls     |
|---------------------------------|----------------|-------------------|-----|----------------------|-----|----------------------|
| Age, mean ± SD (range)          | 46             | 29.3 ± 14.1 (8–62)| 43  | 30.6 ± 13.8 (8–62)   |
| < 18 years, n (%)               | 15             | 33%               | 10  | 23%                  |
| Age of onset, mean ± SD (range) | 46             | 8.2 ± 3.7 (2–17)  | 43  | n.a.                 |
| Male:female ratio (n)           | 46             | 3.6:1 (36 m, 10 f) | 43  | 2.3:1 (30 m, 13 f)   |
| TSGS values, mean ± SD (range) | 46             | 40.2 ± 13.0 (16.8-64.3) | 43  | n.a.                 |
| OCD, n (%), MOCI ≥ 12, mean ± SD (range) | 34  | 74%13.1 ± 2.8 (12-26) | 0   | 0%                   |
| No OCD n (%), MOCI < 12, mean ± SD (range) | 12  | 26%0.42 ± 0.79 (0-2) | 43  | 100%1.42 ± 0.96 (0-4) |
| Psychotropic medication¹, n (%) | 30             | 65%               | 0   | 0%                   |
| Not medicated                   | 16             | 35%               | 43  | 100%                 |

TS = Tourette’s syndrome, OCD = obsessive compulsive disorder, MOCI = Maudsley Obsessive-Compulsive Inventory, TSGS = Tourette Syndrome Global Scale, n = number, f = female, m = male, SD = standard deviation, n.a. = not applicable.

¹including neuroleptics (n = 18), tiapride (n = 11) and antidepressants (n = 7).

Table 2 Concentrations of immune parameters and monocyte markers in TS and healthy controls

| Variable             | Group          | Mean ± SD (range) | Rank sum | z-value | p-value* |
|----------------------|----------------|-------------------|----------|---------|----------|
| Monocytes/ml         | Patients       | 0.57 ± 0.22 (0.1-1)| 50.1     | -2.152  | 0.031    |
|                      | Controls       | 0.47 ± 0.11       | 38.37    |         |          |
| TNF-alpha pg/ml      | Patients       | 0.43 ± 0.18       | 33.09    | -2.421  | 0.015    |
|                      | Controls       | 0.56 ± 0.25       | 45.39    |         |          |
| IL-6 pg/ml           | Patients       | 1.89 ± 1.71       | 39.41    | -1.215  | n.s.     |
|                      | Controls       | 1.74 ± 1.64       | 33.43    |         |          |
| IL1-ra ng/ml         | Patients       | 0.03 ± 0.09       | 36.11    | -2.813  | 0.005    |
|                      | Controls       | 0.04 ± 0.06       | 51.24    |         |          |
| sCD14 ng/ml          | Patients       | 6.37 ± 1.43       | 30.25    | -4.934  | <0.0001  |
|                      | Controls       | 8.40 ± 2.00       | 56.68    |         |          |
| CRP mg/dl            | Patients       | 0.43 ± 0.27       | 45.53    | -2.013  | 0.044    |
|                      | Controls       | 0.37 ± 0.37       | 37.85    |         |          |
| Neopterin nmol/L     | Patients       | 6.03 ± 2.19       | 48.51    | -2.084  | 0.037    |
|                      | Controls       | 5.19 ± 1.84       | 37.36    |         |          |

SD = standard deviation, n.s. = not significant; *Mann–Whitney U Test.
TS, TS with comorbid OCD, and OCD have to be seen as spectrum disorders with common causes or different pathophysiological mechanisms.

Since cytokines have to be seen as a network [38], TNF-alpha levels have to be discussed within the context of our other findings. Also, the decreased levels of IL1-ra suggest a decreased release of monocyte-derived cytokines and point to a decreased production of IL-1. Since IL-1 is released in a paracrine manner, the levels of circulating IL-1 in the blood often are below the limit of detection.

### Table 3 Analysis of TNF-alpha, sCD14, IL1-ra, and neopterin in co-morbid OCD subgroups

| Group                        | TNF-alpha (pg/ml) | sCD14 (ng/ml) | IL1-ra (ng/ml) | Neopterin (nmol/l) |
|------------------------------|------------------|---------------|----------------|-------------------|
| **TS without OCD**           |                  |               |                |                   |
| mean ± SD                    | 0.52 ± 0.17      | 6.9 ± 1.3     | 0.013 ± 0.014  | 5.10 ± 1.28       |
| rank sum                    | 18.82            | 21.05         | 22.25          | 16.50             |
| **TS with OCD**              |                  |               |                |                   |
| mean ± SD                    | 0.40 ± 0.18      | 6.3 ± 1.4     | 0.034 ± 0.095  | 6.36 ± 2.15       |
| rank sum                    | 26.28            | 26.38         | 22.59          | 24.13             |
| p-value* (n)                | n.s. (9/31)      | n.s. (12/32)  | n.s. (12/32)   | n.s. (12/32)      |
| **Control vs.**              |                  |               |                |                   |
| mean ± SD                    | 0.35 ± 0.24      | 8.4 ± 2.0     | 0.041 ± 0.057  | 5.16 ± 1.75       |
| rank sum                    | 40.49            | 47.67         | 42.73          | 31.69             |
| **TS without OCD**           |                  |               |                |                   |
| mean ± SD                    | 0.52 ± 0.17      | 6.9 ± 1.3     | 0.013 ± 0.014  | 5.10 ± 1.28       |
| rank sum                    | 27.35            | 23.33         | 30.64          | 44.19             |
| p-value* (n)                | 0.006 (37/31)    | 0.000 (41/32) | 0.016 (42/32)  | 0.013 (43/31)     |

**TS = Tourette’s syndrome, OCD = obsessive compulsive disorder, n = number, SD = standard deviation, n.s. = not significant, *Mann–Whitney U Test.**

### Table 4 Analysis of TNF-alpha, sCD14, IL1-ra, and neopterin in age subgroups

| Group                        | TNF-alpha (pg/ml) | sCD14 (ng/ml) | IL1-ra (ng/ml) | Neopterin (nmol/l) |
|------------------------------|------------------|---------------|----------------|-------------------|
| **Healthy children vs.**     |                  |               |                |                   |
| mean ± SD                    | 0.67 ± 0.24      | 0.056 ± 0.051 | 8.0 ± 1.4      | 4.70 ± 1.09       |
| rank sum                    | 24.00            | 29.45         | 23.63          | 16.50             |
| **Healthy adults**           |                  |               |                |                   |
| mean ± SD                    | 0.67 ± 0.24      | 0.056 ± 0.051 | 8.0 ± 1.4      | 4.70 ± 1.09       |
| rank sum                    | 16.00            | 17.05         | 17.72          | 11.25             |
| **TS children vs.**          |                  |               |                |                   |
| mean ± SD                    | 0.46 ± 0.20      | 0.056 ± 0.136 | 6.3 ± 1.0      | 5.35 ± 1.79       |
| rank sum                    | 22.50            | 25.07         | 20.37          | 17.54             |
| **TS adults**                |                  |               |                |                   |
| mean ± SD                    | 0.41 ± 0.18      | 0.014 ± 0.096 | 6.6 ± 1.6      | 6.32 ± 2.07       |
| rank sum                    | 19.42            | 21.17         | 24.61          | 24.16             |
| p-value* (n)                | n.s. (14/26)     | n.s. (15/29)  | n.s. (15/29)   | n.s. (14/29)      |
| **Healthy children vs.**     |                  |               |                |                   |
| mean ± SD                    | 0.67 ± 0.24      | 0.056 ± 0.051 | 8.0 ± 1.4      | 4.70 ± 1.09       |
| rank sum                    | 16.00            | 17.05         | 17.72          | 11.25             |
| **Healthy adults**           |                  |               |                |                   |
| mean ± SD                    | 0.51 ± 0.23      | 0.035 ± 0.058 | 8.6 ± 2.1      | 5.31 ± 1.90       |
| rank sum                    | 30.54            | 35.48         | 39.48          | 26.20             |
| **TS children vs.**          |                  |               |                |                   |
| mean ± SD                    | 0.46 ± 0.20      | 0.056 ± 0.136 | 6.3 ± 1.0      | 5.35 ± 1.79       |
| rank sum                    | 10.00            | 10.30         | 9.37           | 13.39             |
| p-value* (n)                | 0.042 (10/14)    | 0.023 (10/15) | 0.003 (9/15)   | n.s. (10/14)      |
| **Healthy adults**           |                  |               |                |                   |
| mean ± SD                    | 0.51 ± 0.23      | 0.035 ± 0.058 | 8.6 ± 2.1      | 5.31 ± 1.90       |
| rank sum                    | 30.54            | 35.48         | 39.48          | 26.20             |
| **TS adults**                |                  |               |                |                   |
| mean ± SD                    | 0.41 ± 0.18      | 0.014 ± 0.096 | 6.6 ± 1.6      | 6.32 ± 2.07       |
| rank sum                    | 23.33            | 26.05         | 21.64          | 36.29             |
| p-value* (n)                | 0.038 (32/29)    | 0.000 (32/29) | 0.027 (32/29)  |                   |

**TS = Tourette’s syndrome, n = number, SD = standard deviation, n.s. = not significant, *Mann–Whitney U Test.**
detection, are unstable and show a short half-life; therefore, the validity of estimating IL-1 serum levels is critically discussed. IL1-ra is a more stable and reliable laboratory parameter. It is produced and released from activated cells of the monocyte lineage [39]. No differences in IL-6 levels were detected between TS patients and healthy controls. IL-6 is assigned pro- and anti-inflammatory characteristics and plays a key role in the acute phase response, especially in direct resolutions of acute infections and septic shock. It is likely to play a detrimental role in chronic disease [40].

The most prominent finding—the lower levels of sCD14 in TS—could also reflect a decreased monocyte activation state and a possible susceptibility to infectious agents. The reduced sCD14 levels in TS patients may point to a blunted innate immunity and could indicate incomplete elimination of infectious agents and a chronic latent infectious state in TS. The most common and sensitive marker of inflammation is CRP. Although CRP levels were within the normal range in our sample of TS patients, the distinct but significant increase compared to controls could point to a latent underlying inflammatory process, similar to the role of high sensitivity CRP in the pathogenesis of atherosclerosis [41]. Neopterin, an unspecific marker of inflammation found in various inflammatory conditions such as infection and autoimmune syndromes [42], has been used as a measure of cell-mediated immunity [43]. The higher levels of neopterin in the TS group in our study reflects the activation of a Th-1 or type-1 immune response, since the type-1 cytokine Interferon-γ (INF-γ) induces neopterin production [44]. The findings of increased neopterin values in TS patients in our study are in line with previous findings. Hoekstra et al. reported significantly elevated neopterin levels in TS patients, indicating an immune activation [45].

In summary, our results point to changes in innate immunity in TS patients compared with healthy controls: sCD14 and the products of activated monocytes, TNF-alpha, and IL1-ra showed lower levels. The number of circulating monocytes, however, was increased. Whether this increase in monocytes might be a compensatory mechanism cannot be determined on the basis of the present data and needs to be investigated in future studies. These changes suggest a dysregulated immune system in TS, which could have implications for susceptibility to infections or autoimmunity.

In our study, not just one but several different parameters showed results pointing to the under-activation of components of the monocyte lineage associated with a possible subclinical inflammatory reaction. Moreover, the findings result from different laboratory methods, i.e. an immunoassay technique, the Luminex bead technology, and automated analyzer methods. As a caveat, it has to be noted that TNF-alpha, IL-6, IL1-ra, CRP, and neopterin serum levels were within the normal ranges and often close to the detection limits. Therefore, the increases or decreases in relation to the control group can only be interpreted as clues for potential trends. No functional tests were performed, and the data reflect only a single time point measurement of the peripheral immune system. Nevertheless, little is known about immunopathological mechanisms in TS, so that these preliminary data contribute to the understanding of monocyte regulation and innate immunity in TS.

To build a possible bridge between the peripheral immune system and the nervous system, one interesting fact is that microglia cells derive from the monocyte/macroglial lineage. Furthermore, cerebral hyperintensities in magnetic resonance images, which can be a sign of neuroinflammatory processes, seem to be associated with TS [46]. However, it remains unclear whether tic symptoms are partly due to the damage caused directly by infections or by the generated autoantibodies, or both, or due to changes in the immune balance. In both cases, neuronal signaling would be disturbed and could lead to tics. The central dopamine systems are most likely to play an important role in TS and can be modulated by immune function. In their review, Martino et al. [4] propose a pathophysiological model for immune-mediated dopamine synthesis via CaM kinase II activation. In this model, infections might induce cross-reactive anti-neural antibodies. First-line inflammatory responses might be promoted by infections and may potentiate dopamine release by autonomic fibers and modulate peripheral immune cells.

The immune constellation in our sample could be in accordance with an impaired innate immune response, associated with an imbalance of the specific (type-1 and type-2) immune responses, the type-2 responses possibly leading to infections, autoimmune phenomena, and inflammatory reactions. Nevertheless, one must take into account that TS is a heterogeneous syndrome that may have different underlying pathological mechanisms. The limited size of our sample—in particular with respect to interfering variables such as age, medication and co-morbidity—means that further intense research regarding the role of inflammation, infection, and the immune system in TS is required. Particularly functional tests and the analysis of genetic polymorphisms that encode for inflammatory cytokines or sCD14 would be of interest.

**Conclusions**
The present findings point to monocyte dysregulation in TS. This possible dysbalance in innate immunity could lead to a higher susceptibility to infectious agents and a chronically latent inflammatory state in TS or could predispose to autoimmunity.
Competing interests
The authors declare that they have no competing interests as regards this manuscript.

Acknowledgements
The authors thank Jacqui Kleising, ELS, for editing assistance with the manuscript. We also thank Prof. Dr. Müller-Vahl, Department of Psychiatry and Psychotherapy, Medical School Hannover, and the Tourette-Gesellschaft Deutschland e.V. for supporting this study.

Author details
1 Department of Psychiatry and Psychotherapy, Ludwig Maximilian University, Nussbaumstr. 780336, Munich, Germany. 2Vinzenz von Paul Hospital, Psychiatry, Schwenneninger Str. 5578628, Rottweil, Germany. 3Department of Rheumatology, Ludwig Maximilian University, Pettenkoferstr. 8a80336, Munich, Germany.

Authors’ contributions
JM designed the study and recruited participants. DLK analyzed the results and prepared the manuscript, including a first draft. SD participated in the conception of the study and critically revised the manuscript. MR reviewed the included articles and assisted with the interpretation of the results. RG and MIK designed the study protocol and analyzed the laboratory parameters. NW revised the manuscript critically at each step of the analysis. All authors read and approved the final manuscript.

Received: 9 August 2011 Accepted: 2 April 2012

Published: 2 April 2012

References
1. Robertson MM, Stern JS. Tic disorders: new developments in Tourette syndrome and related disorders. Curr Opin Neurol 1998, 11:373–380.
2. Robertson MM, Epen V, Cavanna AE. The international prevalence, epidemiology, and clinical phenomenology of Tourette syndrome: a cross-cultural perspective. J Psychosom Res 2009, 67:475–483.
3. Freeman RD, Fast DK, Burd L, Kerbeshian J, Robertson MM, Sandor P. An international perspective on Tourette syndrome: selected findings from 3,500 individuals in 22 countries. Dev Med Child Neurol 2000, 42:536–447.
4. Martino D, Dale RC, Gilbert DL, Giovanni G, Leckman JF. Immunopathogenic mechanisms in tourette syndrome: A critical review. Mov Disord 2009, 24:1267–1279.
5. Price RA, Kidd KK, Cohen DJ, Pauls DL, Leckman JF. A twin study of Tourette syndrome. Arch Gen Psychiatry 1985, 42:815–820.
6. Martino D, Church AJ, Defazio G, Dale RC, Quinn NP, Robertson MM, et al. Soluble adhesion molecules in Gilles de la Tourette’s syndrome. J Neurol Sci 2005, 234:79–85.
7. Greenberg BD, Murphy DL, Svedo SE. Symptom exacerbation of vocal tics and other symptoms associated with streptococcal pharyngitis in a patient with obsessive-compulsive disorder and tics. Am J Psychiatry 1998, 155:1459–1460.
8. Mell IK, Davis RL, Ovens D. Association between streptococcal infection and obsessive-compulsive disorder, Tourette’s syndrome, and tic disorder. Pediatrics 2005, 116:56–60.
9. Church AJ, Dale RC, Giovanni G. Anti-basal ganglia antibodies: a possible diagnostic utility in idiopathic movement disorders? Arch Dis Child 2004, 89:611–614.
10. Church AJ, Dale RC, Lees AJ, Giovanni G, Robertson MM: Tourette’s syndrome: a cross sectional study to examine the PANDAS hypothesis. J Neurol Neurosurg Psychiatry 2003, 74:602–607.
11. Svedo SE, Leonard H, Gavney M, Mittleman B, Allen AJ, Perlmutt S, et al. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases. Am J Psychiatry 1998, 155:264–271.
12. Müller N, Riedel M, Forderreuther S, Blendinger C, Abele-Horn M. Tourette’s syndrome and mycoplasma pneumoniae infection. Am J Psychiatry 2000, 157:481–482.
13. Müller N, Riedel M, Blendinger C, Oberle K, Jacobs E, Abele-Horn M. Mycoplasma pneumoniae infection and Tourette’s syndrome. Psychiatry Res 2004, 129:119–125.
14. Martino D, Defazio G, Giovanni G. The PANDAS subgroup of tic disorders and childhood-onset obsessive-compulsive disorder. J Psychosom Res 2009, 67:547–557.
15. Riedel M, Straube A, Schwarz MJ, Wilske B, Muller N. Lyme disease presenting as Tourette’s syndrome. Lancet 1998, 351:418–419.
16. Budman CL, Kerjakovic M, Bruun RD. Viral infection and tic exacerbation. J Am Acad Child Adolesc Psychiatry 1997, 36:162.
17. Krause D, Matz J, Weidinger E, Wagner J, Wildenauer A, Obermeier M, et al. Association between intracellular infectious agents and Tourette’s syndrome. Eur Arch Psychiatry Clin Neurosci 2010, 260:359–363.
18. Pollmacher T, Haack M, Schuld A, Reichenberg A, Yirmiya R. Low levels of circulating inflammatory cytokines—do they affect human brain functions? Brain Behav Immun 2002, 16:252–35.
19. Leckman JF, Katsovich L, Kawkova L, Lin H, Zhang H, Kronig H, et al. Increased serum levels of interleukin-12 and tumor necrosis factor-alpha in Tourette’s syndrome. Biol Psychiatry 2005, 57:667–673.
20. Brambilla F, Pernia G, Bellodi L, Arancio C, Bertani A, Perini G, et al. Plasma interleukin-1 beta and tumor necrosis factor concentrations in obsessive-compulsive disorders. Biol Psychiatry 1997, 42:576–591.
21. Dens D, Fluitman S, Kavelaars A, Heijnen C, Westenberg H. Decreased TNF-alpha and NK activity in obsessive-compulsive disorder. Psychoneuroendocrinology 2004, 29:945–952.
22. Monteleone P, Catapano F, Fabrazzo M, Tortorella A, Maj M. Decreased blood levels of tumor necrosis factor-alpha in patients with obsessive-compulsive disorder. Neuropsychobiology 1998, 37:182–185.
23. Müller N, Putz A, Kathmann N, Leible R, Gunther W, Straube A. Characteristics of obsessive-compulsive symptoms in Tourette’s syndrome, obsessive-compulsive disorder, and Parkinson’s disease. Psychiatry Res 1997, 70:105–114.
24. Gabbay V, Coffey BJ, Guttmann LE, Gottlieb L, Katz Y, Babb JS, et al. A cytokine study in children and adolescents with Tourette’s disorder. Prog Neuropsychopharmacol Biol Psychiatry 2000, 23:957–971.
25. Vermeiren NG, Blijdt J, Limburg PC, Minderaa RB, Kallenborg CG, Hoekstra PJ. Cytokines and soluble adhesion molecules in children and adolescents with a tic disorder. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34(8):1390–1395.
26. Schroder NW, Schumann RH: Non-LPS targets and actions of LPS binding protein (LBP). Journal of Endotoxin Research 2005, 11:327–342.
27. Pugin J, Ulevitch RJ, Tobias PS. Activation of endothelial cells by endotoxin: direct versus indirect pathways and the role of CD14. Prog Clin Biol Res 1995, 392:589–593.
28. Loprovto H, Stelter F, Schoneck U, Schulter C, Ernst M, Schutt C, et al. Endotoxin activates human vascular smooth muscle cells despite lack of expression of CD14 mRNA or endogenous membrane CD14. Infect Immun 1999, 67:1020–1026.
29. Zdolsek HA, Jennewein MC. Reduced levels of soluble CD14 in atopic children. Clin Exp Allergy 2004, 34:532–539.
30. Jones CA, Holloway JA, Popplewell EI, Diaper ND, Holloway JW, Vance GH, et al. Reduced soluble CD14 levels in amniotic fluid and breast milk are associated with the subsequent development of atopy, eczema, or both. Am J Clin Immunol 2002, 10:858–866.
31. Kawkova L, Leckman JF, Kronig H, Katsovich L, Bessen DE, Ghebremichael M, et al. Decreased numbers of regulatory T cells suggest impaired immune tolerance in children with tourette syndrome: a preliminary study. Biol Psychiatry 2007, 61:273–278.
32. American Psychiatric Association: Diagnostic and statistical manual of mental disorders; 4th edition. Washington: American Psychiatric Association Press; 2000.
33. Rankins D, Bradshaw JL, Georgiou-Karistianis N. Local–global processing in obsessive-compulsive disorder and comorbid Tourette’s syndrome. Brain Cogn 2005, 59(1):43–51.
34. Hodgson RJ, Rachman S. Obsessional-compulsive complaints. Behav Res Ther 1977, 15:389–395.
35. Tadai T, Nakamura M, Okazaki S, Nakajima T. The prevalence of obsessive-compulsive disorder in Japan: a study of students using the Maudsley Obsessional-Compulsive Inventory and DSM-III-R. Psychiatry Clin Neurosci 1999, 43:39–41.
36. Pollmacher T, Hinz-Seidl D, Mullington J. Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. J Clin Psychopharmacol 1996, 16:403–409.
37. Geller DA, Biederman J, Farace S, Agranat A, Craddock K, Hagermoser L, et al. Developmental aspects of obsessive compulsive disorder: findings in children, adolescents, and adults. J Nerv Ment Dis 2001, 189:471–477.
38. Müller N, Ackenheil M: Psychoneuroimmunology and the cytokine action in the CNS: implications for psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 1998, 22:1–33.

39. Dinarello CA: Interleukin-1 and interleukin-1 antagonism. Blood 1991, 77:1627–1652.

40. Jones SA: Directing transition from innate to acquired immunity: defining a role for IL-6. J Immunol 2005, 175:3463–3468.

41. Mangge H, Schauenstein K, Stroedter L, Griesl A, Maerz W, Borkenstein M: Low grade inflammation in juvenile obesity and type 1 diabetes associated with early signs of atherosclerosis. Exp Clin Endocrinol Diabetes 2004, 112:378–382.

42. Schroecksnadel K, Frick B, Winkler C, Fuchs D: Crucial role of interferon-gamma and stimulated macrophages in cardiovascular disease. Curr Vasc Pharmacol 2006, 4:205–213.

43. Fuchs D, Hausen A, Reibnegger G, Werner ER, Dierich MP, Wachter H: Neopterin as a marker for activated cell-mediated immunity: application in HIV infection. Immunol Today 1988, 9:150–155.

44. Wirleitner B, Rudatke V, Neusauter G, Mus C, Kalnins U, Erglis A, et al: Immune activation and degradation of tryptophan in coronary heart disease. Eur J Clin Invest 2003, 33:550–554.

45. Hoekstra PJ, Anderson GM, Troost PW, Kallenber CG, Minderaa RB: Plasma kynurenine and related measures in tic disorder patients. Eur Child Adolesc Psychiatry 2007, 16:Suppl 1:71–77.

46. Amat JA, Bronen RA, Saku S, Sato N, Zhu H, Gozman DA, et al: Increased number of subcortical hyperintensities on MRI in children and adolescents with Tourette’s syndrome, obsessive-compulsive disorder, and attention deficit hyperactivity disorder. Ann J Psychiatry 2006, 163:1106–1108.

doi:10.1186/1471-244X-12-29
Cite this article as: Matz et al. Altered monocyte activation markers in Tourette’s syndrome: a case–control study. BMC Psychiatry 2012 12:29.